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ABSTRACT
Objectives: Detectable minimal residual disease (MRD) after therapy for acute lymphoblastic
leukemia (ALL) is the strongest predictor of hematologic relapse. This study evaluated
outcomes of patients with B-cell precursor ALL with MRD of ≥10−4
Methods: Study population was from ALL study groups in Europe managed in national study
protocols 2000–2014. MRD was measured by polymerase chain reaction or ﬂow cytometry.
Patients were age ≥15 years at initial ALL diagnosis. Patients were excluded if exposed to
blinatumomab within 18 months of baseline or prior alloHSCT.
Results: Of 272 patients in CR1, baseline MRD was ≥10−1, 10−2 to <10−1, 10−3 to <10−2, and 10−4
to <10−3 in 15 (6%), 71 (26%), 109 (40%), and 77 (28%) patients, respectively. Median duration of
complete remission (DoR) was 18.5 months (95% conﬁdence interval [CI], 11.9–27.2), median
relapse-free survival (RFS) was 12.4 months (95% CI, 10.0–19.0) and median overall survival (OS)
was 32.5 months (95% CI, 23.6–48.0). Lower baseline MRD level (P≤ .0003) and white blood
cell count <30,000/µL at diagnosis (P≤ .0053) were strong predictors for better RFS and DoR.
Allogeneic hematopoietic stem cell transplantation (alloHSCT) was associated with longer RFS
(hazard ratio [HR], 0.59; 95% CI, 0.41–0.84) and DoR (HR, 0.43; 95% CI, 0.29–0.64); the
association with OS was not signiﬁcant (HR, 0.72; 95% CI, 0.50–1.05).
Discussion: In conclusion, RFS, DoR, and OS are relatively short in patients with MRD-positive ALL,
particularly at higher MRD levels. AlloHSCT may improve survival but has limitations. Alternative
approaches are needed to improve outcomes in MRD-positive ALL.
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Introduction
Outcomes for adult patients with acute lymphoblastic
leukemia (ALL) have improved. However, some
patients remain resistant to standard chemotherapy.
Despite hematologic complete remission (CR) rates
of 80–90% with intensive induction/consolidation
chemotherapy, approximately 30–50% of adult and
10–20% of pediatric patients at CR1 exhibit minimal
residual disease (MRD) [1–8]. MRD is deﬁned as the
presence of leukemic cells in patients with hematologic
CR below 5%, which is the detection level of
microscopy. Several methods for standardized and
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quantitative measurement of MRD at a sensitivity of
10−4 (i.e. 0.01%) are available, such as ﬂow cytometry
or real-time quantitative polymerase chain reaction
(RQ-PCR) of individual clonal rearrangements of immu-
noglobulin [9].
MRD indicates resistance to standard chemotherapy
and is the most important risk factor for hematologic
relapse in adult and pediatric ALL [2,4,10,11–14]. Stan-
dards for a description of MRD status have been
described [15]. Patients with high MRD levels after
induction and consolidation (i.e. MRD persistence)
have a higher risk of hematologic relapse (70–100%),
whereas patients with complete MRD response are
far less likely to have a hematologic relapse (2–8%)
[1,3,4–6,10,16]. Conversion from MRD negativity to
MRD positivity (i.e. MRD reappearance) is highly predic-
tive of subsequent hematologic relapse [5,7]. Time
from MRD positivity to hematologic relapse is also cor-
related with MRD level [5].
Most study groups recommend allogeneic hemato-
poietic stem cell transplant (alloHSCT) as themost inten-
sive treatment approach available for the management
of MRD [17–19]. Patients who receive alloHSCT have
better outcomes compared with those who do not
[20]. However, alloHSCT is not always an option due to
associated toxicities, lack of suitable donors, or other
reasons. Patients may relapse awaiting alloHSCT, par-
ticularly those with higher MRD levels. Additionally,
patients with detectable MRD before alloHSCT may
have a higher risk of relapse after alloHSCT [5,13,21].
The objectives of this study were to estimate the
duration of hematologic CR (DoR), hematologic
relapse-free survival (RFS), and overall survival (OS)
for patients with MRD-positive B-cell precursor (BCP)
ALL treated with standard of care in Europe. In addition,
several statistical methods were used to closely explore
how alloHSCT status may inﬂuence clinical outcomes.
Methods
Study design
We analyzed a cohort of adults with ALL who had
reached CR but had detectable MRD after the standard
of care treatment according to national study proto-
cols. The study population was from ALL study
groups in Europe (Czech Republic, France, Germany,
Italy, Poland, Russia, Spain and the United Kingdom)
with protocols that included prospective MRD testing
in national reference laboratories. Entry criteria, data
collection methods, and analyses were deﬁned in
a joint protocol (clinicaltrials.gov identiﬁer:
NCT02010931). Ethical approval was obtained accord-
ing to individual country requirements.
Patient-level data were obtained from clinical data-
bases and entered by central staﬀ of each study group
into a study-speciﬁc electronic case report form to
ensure a standardized and quality-controlled data col-
lection process. Variables included information on
demographics, disease characteristics, history of ALL
treatment prior to the detection of MRD, diagnostics
and level of MRD, details of transplantation for patients
who underwent alloHSCT after theirMRDdetection, and
clinical event data including occurrence of hematologic
relapse, date of death, or date last known to be alive.
Patient eligibility
Patients were eligible if they had Ph/BCR-ABL–negative
BCP ALL in hematologic CR (<5% blasts in bone marrow
after ≥3 intensive chemotherapy blocks) and no extra-
medullary involvement. Other key eligibility criteria
were: MRD of ≥10−4 by RQ-PCR of clonally rearranged
immunoglobulin or ≥10−3 by ﬂow cytometry at a refer-
ence lab; age ≥15 years at initial ALL diagnosis; initial
ALL diagnosis in the years 2000–2014; availability of
data for history of ALL treatment (including response
to ﬁrst therapy and number of prior relapses); and
relapse status and disease follow-up after MRD detec-
tion. To focus on standard therapies, patients were
excluded if exposed to blinatumomab within 18
months of MRD detection. Patients with MRD after
prior alloHSCT were excluded.
Statistical analyses
Patients were included in all analyses regardless of
whether they received a transplant after MRDdetection.
The primary outcome, RFS, was deﬁned as the time from
baseline MRD detection until hematologic relapse or
death due to any cause; patients alive without relapse
were censored at their last disease assessment. The sec-
ondary outcome, OS, was deﬁned as the time from
baseline MRD detection until death; patients without
a recorded death were censored at last follow-up. The
analysis of DoR was deﬁned as the time from baseline
MRD detection until relapse; patients who died in CR
were censored at the date of death. RFS, OS, and DoR
were summarized with Kaplan-Meier curves and pro-
portions; point estimates were accompanied by 2-
sided 95% conﬁdence intervals (CI).
Baseline MRD was the ﬁrst measurement of MRD-
positivity after CR. Baseline MRD status was deﬁned
as MRD persistence (MRD positivity without prior docu-
mented negativity) or MRD reappearance (return to
MRD positivity after achievement of complete MRD
response) [15]. In univariate Cox regression models,
the potential association between RFS, DoR, and OS
with each of the following factors was investigated:
age at diagnosis (15–34, 35–54, 55–64, or ≥65 years);
sex (female vs. male), MRD status (persistence vs.
reappearance); MRD at baseline (≥10−1, 10−2 to
<10−1, 10−3 to <10−2, or 10−4 to <10−3), and white
blood cell (WBC) count at diagnosis (≥30,000/µL vs.
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<30,000/µL). Using forward selection, factors signiﬁcant
at P < .10 were included in a multivariable Cox
regression model describing RFS, DoR or OS.
Several methods were employed to explore the
eﬀect of receiving alloHSCT after detection of MRD.
(1) Conditional landmark analyses of alloHSCT deﬁned
the landmark at 3 months, which was approximately
the median time to alloHSCT from baseline (3.4
months; interquartile range, 1.7–6.3); additionally, a
landmark at 6 months was assessed which included
most patients that underwent a transplant. For each
analysis, patients with an event (DoR, RFS, OS) before
the deﬁned landmark were excluded, transplant
status was assessed at the time of the landmark (3
months and 6 months), wherein a patient was con-
sidered to be transplanted only if the transplant was
conducted on or before the landmark time. Any
patients who underwent a transplant after the land-
mark were included in the nontransplant group. (2)
Mantel–Byar analysis handles alloHSCT as a time-
dependent covariate. A patient is attributed to the non-
transplant group until the time of transplant, once
transplanted, is considered part of the transplant
group. No patients were excluded from this analysis
as in the conditional landmark analysis. This method
accounts for time bias observed in ﬁxed-time analyses
because patients undergoing alloHSCT must survive
long enough to receive alloHSCT [22]. The Simon–
Makuch method (with and without a 3-month land-
mark) was used to graphically display results from the
Mantel–Byar test [23]. (3) A multivariate Cox pro-
portional hazards model, adjusting for the baseline
factors that were identiﬁed in the multivariate Cox
model as described above, included alloHSCT as a
time-dependent covariate. Statistical signiﬁcance was
measured at P < .05. No adjustment was considered
for multiplicity.
Results
Patient population
Data were captured from 287 patients. Analyses of
baseline characteristics included 272 patients with
quantiﬁable baseline MRD and excluded 15 patients
whose MRD was qualitatively reported to be ≥10−4
but had non-quantiﬁable MRD. Of the 272 patients,
time-to-event analyses for DoR, RFS, or OS included
270 patients and excluded 2 patients with quantiﬁable
baseline MRD missing the date for MRD.
Patient characteristics are shown in Table 1 and Sup-
plemental Table 1. The median age at diagnosis was 33
years (IQR, 24–45). Slightly more than half of the
patients were male (58%) and aged <35 years (56%).
MRD was assessed by RQ-PCR in most patients (79%)
and the baseline MRD was ≥10−3 in 72%. Most patients
(80%) had MRD persistence; 19% had MRD
reappearance and 1% had an unknown MRD status.
Median time from initial ALL diagnosis to MRD positiv-
ity was 4.2 months. Median follow-up was 23.0 months
for patients included in time-to-event analyses.
Duration of remission
Median DoR was 18.5 months (95% CI, 11.9–27.2) after
baseline MRD assessment (Figure 1(A)). At 36 months,
38% of patients remained in hematologic CR (95% CI,
32% to 45%). Median DoR was longer in patients with
lower baseline MRD: 2.0, 10.9, 18.5, and 42.4 months
after baseline MRD of ≥10−1, 10−2 to <10−1, 10−3 to
<10−2, and 10−4 to <10−3, respectively (P < .0001;
Figure 2(A) and Table 2). Median DoR was also longer
in patients with WBC <30,000/µL vs. ≥30,000/µL at
diagnosis (P = .003), younger vs. older patients (P
= .21), and patients with MRD persistence vs. MRD
reappearance (P = .03; Table 2 and Supplemental
Figure 1). In a multivariable model, younger age (P
= .08), lower WBC count at diagnosis (P = .005), lower
baseline MRD (P = .002), and MRD persistence vs.
reappearance (P = .03) were associated with longer
DoR (Table 3). Year of diagnosis, which was not a
signiﬁcant factor for DoR in the univariate analysis
(P = .86), was not included in the multivariable model.
Median DoR was slightly shorter when patients were
censored at HSCT (Supplemental Figure 2).
Relapse-free survival
Median RFS was 12.4 months (95% CI, 10.0–19.0) after
baseline MRD assessment (Figure 1(B)). At 36 months,
estimated RFS was 33% (95% CI, 27–39%). Median
RFS was longer in patients with a lower baseline
MRD: 2.0, 9.7, 10.6, and 31.3 months after baseline
MRD of ≥10−1, 10−2 to <10−1, 10−3 to <10−2, and
10−4 to <10−3, respectively (P = .0003; Figure 2(B) and
Table 2). Lower WBC count at original ALL diagnosis
was also associated with longer median RFS (P = .005;
Table 2 and Supplemental Figure 1). In a multivariable
model, lower baseline MRD (P = .003), lower WBC at
diagnosis (P = .007), MRD persistence vs. reappearance
(P = .11) and younger vs. older age (P = .05) were associ-
ated with longer RFS (Table 3). As with DoR, year of
diagnosis was not signiﬁcant in the univariate analysis
(P = .91) and was not included in the multivariable
model. Median RFS was slightly shorter when patients
were censored at HSCT (Supplemental Figure 2).
Overall survival
Median OS was 32.5 months (95% CI, 23.6–48.0) after
baseline MRD assessment (Figure 1(C)), with 48% of
patients alive at 36 months (95% CI, 41–54%). Among
272 patients with quantiﬁable baseline MRD, 155
(57%) patients died, including 23 (8%) without docu-
mented relapse (Supplemental Table 2). Median OS
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was longer in patients with a lower baseline MRD (15.5,
21.5, 31.2, and 50.7 months after baseline MRD of
≥10−1, 10−2 to <10−1, 10−3 to <10−2, and 10−4 to
<10−3, respectively) but the trend was not statistically
signiﬁcant (P = .14; Figure 2(C) and Table 2). When
patients with baseline MRD ≥10−3 or <10−3 were com-
pared, those with higher baseline MRD had signiﬁ-
cantly worse OS (50.7 vs. 26.5 months; P = .03; Table
2). Younger age (P = .002) and lower WBC at diagnosis
(P = .02) were associated with longer median OS (Sup-
plemental Figure 1). In a multivariable model, lower
WBC at diagnosis (P = .002), younger age (P = .0005),
and later year of diagnosis (P = .06) were associated
with longer median OS (Table 3). Median OS was
slightly shorter when patients were censored at HSCT
(Supplemental Figure 2).
Other analyses
WBC at diagnosis, which was prognostic for RFS, DoR,
and OS, was cross-tabulated with other predictors for
patient outcomes. Age, sex, baseline MRD, and trans-
plant status were not signiﬁcantly diﬀerent between
patients with higher (≥30,000/µL) or lower (<30,000/
µL) WBC at diagnosis (Supplemental Table 3).
However, patients with a year of diagnosis after 2010
had higher WBC count than those diagnosed in
2004–2010 (P = .02).
Transplant outcomes
A total of 110 patients (40%) received alloHSCT in
ongoing hematologic CR and 162 (60%) did not (Sup-
plemental Table 4). Patients undergoing transplant
were slightly younger at diagnosis compared to non-
transplanted patients: 64% vs. 50% were age <35
years (P = .06) and median age was 31.5 vs. 33.0
years. Median time from baseline MRD assessment
to alloHSCT was 3.4 months (range, 0.1–39.8). From
year 2005 onward, proportionally more patients
underwent transplant compared to patients diag-
nosed in the years 2000 to 2004 (45% [67/149] vs.
31% [31/97]; P = .06).
Table 1. Patient demographics, disease characteristics, and MRD status.
All Patients
(N = 272)
In CR1
(N = 270)
Received
alloHSCT
(N = 110)
Follow-up, months, median (Q1–Q3) 22.5 (9.6–40.6) 23.0 (10.0–50.7) 30.2 (14.8–52.4)
Sex, n (%)
Male 159 (58) 157 (58) 69 (63)
Female 113 (42) 113 (42) 41 (37)
Age at diagnosis, years
Median (range) 33 (15–65) 33 (15–65) 31.5 (16–63)
Age group at diagnosis, n (%)
15–34 years 151 (56) 149 (55) 70 (64)
35–54 years 86 (32) 86 (32) 32 (29)
55–64 years 34 (13) 34 (13) 8 (7)
≥65 years 1 (<1) 1 (<1) 0 (0)
Time from diagnosis to baseline, monthsa
Median (Q1–Q3) 4.2 (3.4–5.3) 4.2 (3.4–5.3) 4.0 (3.3–4.9)
<6 months, n (%) 217 (80) 216 (80) 95 (86)
6 months, n (%) 53 (19) 52 (19) 15 (14)
Year of diagnosis, n (%)
2000–2004 99 (36) 99 (37) 31 (28)
2005–2010 149 (55) 148 (55) 67 (61)
2011 or later 24 (9) 23 (9) 12 (11)
WBC count at diagnosisa, n (%)
<30,000/µL 198 (73) 198 (73) 74 (67)
≥30,000/µL 72 (26) 71 (26) 35 (32)
Cytogenetic/molecular aberrationsa, n (%)
t(4;11) KMT2A/AFF1 19 (7) 18 (7) 11 (10)
Other 36 (13) 36 (13) 12 (11)
No 216 (79) 215 (80) 87 (79)
Baseline MRD statusa, n (%)
Persistence 217 (80) 217 (80) 91 (83)
Reappearance 51 (19) 51 (19) 16 (15)
Methodology, n (%)
RQ-PCR 215 (79) 214 (79) 86 (78)
Flow cytometry 57 (21) 56 (21) 24 (22)
Baseline MRD levela
Median (range) 0.0027
(0.000–2.400)
0.0027
(0.000–2.400)
0.0020
(0.000–0.055)
≥10−1, n (%) 15 (6) 15 (6) 4 (4)
≥10−2 to <10−1, n (%) 71 (26) 70 (26) 30 (27)
≥10−3 to <10−2, n (%) 109 (40) 109 (40) 42 (38)
≥10−4 to <10−3, n (%) 77 (28) 76 (28) 34 (31)
Note: Q indicates quartile.
aDoes not include patients with missing data (n = 2 for time from diagnosis to baseline MRD status, n = 3 for WBC count at diagnosis, n = 1 for cytogenetic
aberrations, n = 4 for baseline MRD status, and n = 15 for baseline MRD level). Patients with missing baseline MRD level had documented MRD but no exact
level was given.
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Transplant status was associated with diﬀerent
causes of death. At last follow-up, 58% of transplanted
patients and 33% of nontransplanted patients
remained alive. Death without documented relapse
was reported for 14% of transplanted patients and
5% of nontransplanted patients, while 28% of trans-
planted patients and 62% of nontransplanted patients
died after relapse (P < .0001).
Median DoR in all transplanted patients was 68.4
months (95% CI, 34.1 to NE) and 36-month DoR was
59% (95% CI, 48–69%). In transplanted patients with
baseline MRD of ≥10−1, 10−2 to <10−1, 10−3 to <10−2,
and 10−4 to <10−3, median DoR was not reached,
33.1 months, not reached, and 75 months, respectively.
Median DoR in all nontransplanted patients was 7.4
months (95% CI, 4.8–10.9) and 36-month DoR was
22% (95% CI, 15–28%).
Median RFS from the date of alloHSCT in all trans-
planted patients was 34.4 months (95% CI, 21.8 to
NE) and 36-month RFS was 49% (95% CI, 39–60%). In
Figure 1. Outcomes among patients with MRD. (A) DoR. (B) RFS. (C) OS. Note: Censored patients are indicated by vertical bars.
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transplanted patients with baseline MRD of ≥10−1,
10−2 to <10−1, 10−3 to <10−2, and 10−4 to <10−3,
median RFS from date of alloHSCT was not reached,
27.7, 47.9, and 75.4 months, respectively. In nontrans-
planted patients, median RFS was 6.7 months overall
(95% CI, 4.6–9.2) and 36-month RFS was 20% (95% CI,
13–26%).
Median OS from the date of alloHSCT in trans-
planted patients was 76.1 months overall (95% CI,
41.1 to NE) and 36-month OS was 61% (95% CI, 51–
71%). In transplanted patients with baseline MRD of
≥10−1, 10−2 to <10−1, 10−3 to <10−2, and 10−4 to
<10−3, median OS from date of alloHSCT was not
reached, 33.0, 54.4, and 75.4 months, respectively. In
nontransplanted patients, median OS was 20.4
months overall (95% CI, 15.3–31.7) and 36-month OS
was 38% (95% CI, 30–46%).
Mantel–Byar analysis indicated improved outcomes
among transplanted patients for DoR (odds ratio [OR],
0.49; 95% CI, 0.33–0.73; P = .0004), RFS (OR, 0.65; 95%
CI, 0.47–0.92; P = .02), and OS (OR, 0.72; 95% CI, 0.51–
1.01; P = .06; Table 4). Mantel–Byar test results were
visualized with Simon–Makuch plots, illustrating
longer DoR, RFS, and OS among transplanted patients
(Figure 3), similar results were observed with a 3-
month landmark (Supplemental Figure 3). Conditional
landmark analyses which considered patients under-
going alloHSCT up to month 3 suggested longer DoR,
Figure 2. Kaplan–Meier plots of outcomes by baseline MRD level. (A) DoR by all MRD levels. (B) RFS by all MRD levels. (C) OS by all
MRD levels. (D) DoR by MRD ≥10−3 or <10−3. (E) RFS by MRD ≥10−3 or <10−3. (F) OS by MRD ≥10−3 or <10−3. Note: Censored
patients are indicated by vertical bars.
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RFS, and OS for patients that underwent alloHSCT.
However, no diﬀerence was observed in transplanted
patients up to month 6 (Supplemental Figure 4). In a
time-dependent Cox model adjusting for baseline
factors, similar improvement after alloHSCT was
observed for DoR (HR, 0.43; 95% CI, 0.29–0.64; P
< .0001; Table 4) and RFS (HR, 0.59; 95% CI, 0.41–0.84;
P = .003). Transplanted patients also appeared to have
longer OS than nontransplanted patients, although
these ﬁndings were not statistically signiﬁcant (HR,
0.72; 95% CI, 0.50–1.05; P = .08).
Discussion
This was an analysis of a large dataset of patients with
Ph-negative BCP-ALL and measurable MRD who
received standard of care therapy at European aca-
demic study group protocols or at major centers. A
broad cross-section of patients were included which
increased robustness and generalizability of these
study results. Baseline MRD level appeared to
inﬂuence DoR, RFS, and OS, demonstrating the prog-
nostic impact of MRD and highlighting the importance
of incorporating MRD assessment into routine care.
Patients with very high baseline MRD (≥10−1) had
very short DoR, whereas those with MRD between
10−4 and 10−3 had much longer DoR. This ﬁnding
underlines that MRD detection is a surrogate for
disease burden and is consistent with previous
research showing that progressively higher MRD are
associated with higher relapse rates [5,10]. In patients
with MRD above 10−2, the median time until hematolo-
gic relapse was weeks (1.6–3.9 months) in this study,
indicating that the time window to change treatment
strategy (eg, alloHSCT) based on MRD is limited. With
higher levels of MRD, the outcome even with alloHSCT
is not nearly as beneﬁcial compared to lower levels of
MRD or undetectable MRD [5,24].
Patients with MRD reappearance in our study popu-
lation had worse outcomes compared to those with
MRD persistence. Detecting MRD reappearance
strongly depends on the frequency of follow-up MRD
testing in patients with complete MRD response.
Follow-up evaluation to detect MRD reappearance is
not routine in many countries and explains the rela-
tively low number of patients with MRD reappearance
in the studied population. The management of MRD
reappearance may diﬀer from MRD persistence.
Whereas MRD persistence is often detected early
after consolidation and patients usually receive contin-
ued intensive treatment, this is often not the case in
MRD reappearance, when patients are oﬀ treatment
Table 2. Median DoR, RFS, and OS according to diﬀerent patient factors.
Variable n
DoR, Months RFS, Months OS, Months
Median (95% CI) Median (95% CI) Median (95% CI)
Age group at diagnosis
15–34 years 151 21.3 (11.9–34.1) 15.9 (10.6–25.7) 54.4 (34.7–98.6)
35–54 years 85 22.1 (9.3–43.9) 11.8 (7.3–25.7) 20.0 (11.5–32.5)
≥55 years 34 10.7 (5.2–19.7) 10.0 (5.2–19.5) 14.7 (10.4–30.8)
P .21 .20 .0024
Sex
Male 159 24.4 (12.8–33.1) 17.5 (9.3–27.2) 45.9 (26.5–75.4)
Female 111 12.3 (10.0–19.7) 11.3 (11.3–13.6) 24.5 (16.8–37.4)
.26 .38 .16
WBC count at diagnosis
<30,000/µL 196 25.7 (16.6–36.8) 17.5 (11.7–26.5) 39.0 (27.8–58.9)
≥30,000/µL 72 9.2 (4.4–14.9) 8.6 (4.3–11.8) 16.1 (12.4–31.9)
P .0033 .0053 .016
Year of diagnosis
2000–2004 97 21.3 (12.3–32.9) 12.6 (10.3–22.1) 26.5 (17.5–34.7)
2005–2010 149 16.6 (9.7–29.7) 11.0 (7.3–19.7) 45.9 (24.3–82.2)
2011 or later 24 NE (5.2–NE) NE (5.2–NE) NE (15.7–NE)
P .86 .92 .31
Baseline MRD level (vs. ≥10−1)
≥10−1 15 2.0 (1.4–4.8) 2.0 (1.4–4.8) 15.5 (7.1–NE)
≥10−2 to <10−1 71 10.9 (7.3–21.2) 9.7 (6.4–17.3) 21.5 (13.7–33.0)
≥10−3 to <10−2 108 18.5 (9.9–30.3) 10.6 (7.3–19.7) 31.2 (18.0–58.9)
≥10−4 to <10−3 76 42.4 (23.6–NE) 31.3 (13.6–75.4) 50.7 (31.7–NE)
P <.0001 .0003 .14
Baseline MRD level (vs. ≥10−2)
≥10−2 86 9.2 (4.8–12.6) 8.2 (4.8–11.8) 21.5 (13.6–34.7)
≥10−3 to < 10−2 108 18.5 (9.9–30.3) 10.6 (7.3–19.7) 31.2 (18.0–58.9)
≥10−4 to < 10−3 76 42.4 (23.6–NE) 31.3 (13.6–75.4) 50.7 (31.7–NE)
P .0003 .0006 .069
Baseline MRD level (vs. ≥10−3)
≥10−3 194 11.7 (8.7–19.5) 9.7 (7.0–12.6) 26.5 (16.9–35.4)
≥10−4 to < 10−3 76 42.4 (23.6–NE) 31.3 (13.6–75.4) 50.7 (31.7–NE)
P .0008 .0008 .031
Baseline MRD status
Persistence 215 22.1 (12.9–30.3) 13.0 (10.7–22.2) 30.8 (21.5–45.9)
Reappearance 51 5.6 (2.8–19.0) 8.5 (2.7–17.3) 43.6 (23.6–NE)
P .028 .11 .49
Note: NE indicates not estimable.
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or in the maintenance phase, which may contribute to
the high risk of immediate hematologic relapse [5,11].
Other factors that were associated with outcomes,
included WBC and age at initial ALL diagnosis. High
WBC at diagnosis is an established factor predicting
poorer prognosis [25]. Although the biologic eﬀect
behind this clinical factor is not described thus far, it
seems that the adverse impact of elevated WBC
count at diagnosis is maintained at the time of MRD
measurement, as it confers more aggressive disease.
Similarly, in relapsed/refractory ALL, the WBC count at
ﬁrst diagnosis maintains an impact on survival [26].
The youngest patients had the longest OS, whereas
the oldest patients had the shortest OS, consistent
with published literature [10]. Possible explanations
are decreased transplant realization rate and lower-
intensity chemotherapy in older patients and increased
alloHSCT-related mortality in the middle age group.
With no recognized standard of care for MRD-posi-
tive ALL during the study period, DoR and RFS
remained relatively stable over the evaluated time
periods from 2000 to 2014. However, more recently
diagnosed patients (2011 or later) appeared to have
slightly longer OS compared to patients diagnosed in
earlier years. An increasing proportion of patients
underwent alloHSCT in general [27] and in this study.
This may be due to the fact that the negative impact
of MRD was acknowledged to an increasing extent,
leading to a clear indication for alloHSCT, which is
now part of diﬀerent guidelines and ﬁrst-line protocols
[18]. Improvements in alloHSCT may have reduced risk
of non-relapse mortality for younger patients [28]. It is
possible that with more follow-up data, the eﬀect of
alloHSCT on survival among MRD-positive patients
could be even greater than observed.
Several diﬀerent statistical analysis techniques were
used to examine the potential role of alloHSCT and
showed a trend toward better outcomes with alloHSCT.
However, these analyses did not adjust for potential bias
such as diﬀerential patient characteristics for transplant
(e.g. younger age). In time-varying Cox models,
Mantel–Byar analysis, and Simon–Makuch plots,
alloHSCT was a time-dependent covariate and reducedTa
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Table 4. Analysis of outcomes for transplanted vs.
nontransplanted patients.
Test of alloHSCT
vs.
non-alloHSCT Statistic
DoRa
(Events =
164c)
RFSa
(Events =
187c)
OSb
(Events =
154c)
Mantel–Byar Odds ratio 0.49 0.65 0.72
(95% CI) (0.33–0.73) (0.47–0.92) (0.51–1.01)
P .0004 .017 .059
Cox proportional
hazards
Hazard
ratio
0.43 0.59 0.72
(95% CI) (0.29–0.64) (0.41–0.84) (0.50–1.05)
P <.0001 .0031 .085
aDoR and RFS were adjusted for age, WBC count at diagnosis, and MRD
level.
bOS was adjusted for age, WBC count at diagnosis, and year of diagnosis.
cN = 270 patients were evaluable for events.
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bias introduced by diﬀerent on-study time to alloHSCT.
Conditional landmark analyses suggested beneﬁt for
patients surviving without event until month three. A
later landmark at month six didn’t show an advantage
for transplanted patients. Patients surviving without
transplantation until this later time-point may represent
a positive selected patient population, which would
include patients who do not require a transplant.
However, this is not the usual situation in clinical prac-
tice where transplantation is performed earlier. Limit-
ations of this method are the deﬁnition of an
adequate landmark as patients with an event before
the landmark are excluded from the analysis, reducing
total evaluable patients. Furthermore, patients receiving
a transplant after the landmark are considered nontrans-
planted, further attenuating the results.
Figure 3. Simon–Makuch plots of outcomes by alloHSCT status (A) DoR. (B) RFS. (C) OS.
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Overall, patients with persistent or recurrent MRD
who underwent alloHSCT achieved a better outcome
in terms of DoR and RFS and was assessed by multiple
methods. Patients receiving alloHSCT also had longer
OS, but was not statistically signiﬁcant. A possibility is
that some non-transplanted patients survived after
relapse accounting for the smaller diﬀerence in OS.
But these events were few and relapse events were
captured in the DoR and RFS analyses. This study did
not collect detailed information on transplant donor
type or non-relapse related mortality. However, the
patient population receiving a transplant was relatively
young and mortality in CR was limited (though higher
than that in nontransplanted patients). Also, risk of
hematologic relapse was higher in nontransplanted
patients. Overall beneﬁts of DoR, RFS, and OS favored
patients undergoing a transplant.
MRD has become a routine part of disease monitor-
ing; in prognostic models, MRD is an important factor in
guiding the development of new protocols/therapies.
Current guidelines from National Comprehensive
Cancer Network [19] and European Society for
Medical Oncology [18] mandate MRD testing for post-
induction follow-up and risk stratiﬁcation. AlloHSCT is
often recommended to improve outcomes of patients
with MRD [1,2,5,29]. MRD detection between ﬂow cyto-
metry or RQ-PCR are highly concordant [30], so the
most readily available standardized assay should be
used. Persistent MRD has been reported as the only
risk factor predictive of a signiﬁcant eﬀect of alloHSCT
in ﬁrst CR [20]. MRD status immediately before sub-
sequent alloHSCT was not documented in our study.
Others have reported, however, that less MRD prior
to transplant was associated with improved OS and
RFS [13,21,24]. In addition, many MRD-positive patients
develop overt hematologic relapse despite continued
chemotherapy while alloHSCT is prepared. This is also
evident from the high relapse rate in MRD-positive
patients in our study. Currently, many new trials are tar-
geting MRD negativity as the primary endpoint.
Altogether, these data indicate the need for
improved treatments for patients with MRD-positive
ALL. Since patients with persistent MRD demonstrate
resistance to chemotherapy, new drugs with diﬀerent
mechanisms of action are of interest. A recent trial
with the bispeciﬁc antibody blinatumomab in MRD-
positive BCP-ALL included patients with MRD in CR1
but in one-third of the patients in CR2/CR3. The
median age was 45 years and the MRD level was
above 10−3. In this unfavorable patient population, bli-
natumomab yielded conversion to MRD-negative
among 78% of patients and median survival of 36.5
months. Additionally, longer survival was observed
for patients with complete MRD response compared
to patients who did not respond [31]. Blinatumomab
was recently approved by the US Food and Drug
Administration and European Medicines Agency for
the treatment of >10−3 MRD in ALL. Trials of blinatumo-
mab and inotuzumab in relapsed/refractory ALL
demonstrated that CR often was accompanied by
MRD response [32,33].
The primary limitation of this study is that it was ret-
rospective. Each country or study group followed their
protocol, which speciﬁed when to conduct MRD assess-
ments. Treatments and procedures for relapse were not
captured or analyzed in this study and data collection
around alloHSCT was limited. Conditioning regimen,
donor type or match can be associated with survival
[34], but these details were not available. Lack of
these data likely biased study results to non-signiﬁ-
cance rather than causing the observed eﬀects. The
use of multiple statistical techniques was necessary
because no single method is best for analyzing time-
varying covariates such as alloHSCT. There may be
some uncertainty on the size of the eﬀect of alloHSCT,
but not on the directional improvement of outcomes.
This study included patients over a 14-year span.
Changes in alloHSCT may not be fully realized in this
study, as the eﬀect of alloHSCT on outcomes was aver-
aged over that time span. The major eﬀect was prob-
ably the higher realization rate of alloHSCT over the
years. Finally, the study sample size was modest,
which limited the power to detect diﬀerences with P-
values <.05.
In conclusion, MRD is a strong prognostic factor for
clinical outcomes. This data provides a reference for
outcomes of adults with MRD-positive BCP-ALL who
receive standard therapies including alloHSCT.
Achievement of MRD negativity is a goal of the
modern treatment strategy, even patients allocated
to alloHSCT consolidation. Use of alloHSCT may
improve outcomes in these patients, but there is
room for further improvement, possibly use of targeted
therapies to enable more MRD-negative alloHSCT.
Although the patient population in this study was rela-
tively young, these conclusions may be even more rel-
evant for older patients with persistent MRD who have
the worst prognoses, likely due to not having the
option to undergo alloHSCT or further intensiﬁcation
of chemotherapy.
Registered at www.clinicaltrials.gov as #NCT02010
931.
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